Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects

NCT02991859 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: Fluticasone furoate (FF) Dry Powder Inhaler
DRUG: Fluticasone propionate (FP) Dry Powder Inhaler
DRUG: Budesonide (BUD) Turbuhaler
DRUG: Placebo (ELLIPTA or DISKUS)

Sponsor

GlaxoSmithKline